shutterstock_158366573

Libtayo becomes first EU-approved therapy for advanced cutaneous squamous cell carcinoma

pharmafile | July 2, 2019 | News story | Manufacturing and Production, Sales and Marketing |  Europe, Libtayo, Regeneron, Sanofi, carcinoma, pharma 

The European Commission has revealed that it has decided to award approval, albeit conditionally, to Sanofi and Regeneron’s Libtayo (cemiplimab) in the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in adult patients who are not eligible for curative surgery or curative radiation.

The EC’s decision took into account the unmet need in the indicated disease, and was based on data drawn from the largest prospective data set available in advanced CSCC – a set comprising data from a non-randomised Phase 2 trial and two advanced CSCC expansion cohorts from a non-randomised Phase 1 trial.  

As part of the conditional approval, Sanofi and Regeneron have confirmed they will introduce a new patient group into an ongoing trial to further assess the efficacy of Libtayo, as per the EMA’s request.

“With no other medical treatments approved for advanced CSCC in the EU, Libtayo represents an important new option for patients affected with this advanced skin cancer who cannot be cured by surgery or radiation,” explained Dr Axel Hauschild, investigator in the trials and Professor and Head of the Interdisciplinary Skin Cancer Center at the University Hospital Schleswig-Holstein in Kiel, Germany. “Results from the Libtayo pivotal trial are very encouraging and demonstrated substantial and durable responses following Libtayo treatment, including in the elderly and regardless of PD-L1 expression levels.”

Advertisement

Matt Fellows

Related Content

Amphista doses first patient in AML trial of protein degrader

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Excellence in Healthcare Partnership Awards – A Collaborative Working Project Between Sanofi and The University Hospital Birmingham Severe Asthma Team

Launched in February 2026 by PMGroup Worldwide Ltd and Visions4Health, the Excellence in Healthcare Partnerships …

Phoenix Labs acquires Kent Pharma

Phoenix Labs has acquired UK pharmaceutical distributor Kent Pharma from private equity firm Duke Street, …

The Gateway to Local Adoption Series

Latest content